Australia fulfils HIV/AIDS funding commitments to Asia-Pacific:
This article was originally published in Clinica
Australia has committed almost Aus$400m (US$325m) to its Asia-Pacific HIV/AIDS programmes. Last year, Aus$600m was allocated, completing Australia's original Aus$1bn pledge to this region. This year, Indonesia will receive Aus$86m to improve its HIV/AIDS services, as part of a partnership between the two countries. The funds are to be distributed by 2010, through Australia's foreign aid agency AusAID. Special focus will be on Papua New Guinea, where there has been a significant increase in the incidence of HIV/AIDS during the past 10 years (see Clinica No 1246, p 10).
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.